Prostate cancer
TulmiSTAR-01
A two-part, Phase 1 dose escalation and expansion followed by a randomized, open-label multicenter, Phase 2 study to assess the safety and efficacy of the combination of tulmimetostat (DZR123) and JSB462 (luxdegalutamide) vs standard of care in patients with progressive metastatic castrate resistant prostate cancer.
Trial overview
Clinical Area
Medical Oncology
Disease
Prostate
Disease site
Genitourinary (GU)
Study Phase
I
Trial Identifiers
Registration number: NCT07206056
Principal Investigator(s)
··
··